ArticleMolecular biology reports1995
The inhibitory domain in the Oct-2 transcription factor represses gene activity in a cell type-specific and promoter-independent manner.
Article in Molecular biology reports, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 11 citations in OpenAlex.
- Cloning and initial characterization of an alternatively spliced transcript encoded by the bovine herpes virus 1 latency-related gene.Journal of neurovirology · 2003Article
- Adjacent proline residues in the inhibitory domain of the Oct-2 transcription factor play distinct functional roles.Nucleic acids research · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Oct-2 transcription factor contains an N-terminal inhibitory domain which can act to inhibit promoter activity when linked to either its corresponding DNA-binding POU domain or the heterologous DNA binding domain of the yeast transcription factor GAL4. This inhibitory effect is independent of the number of DNA binding sites or their context in the target promoter. In contrast the effect is cell type-specific and can be relieved by over-expression of the isolated inhibitory domain in the absence of a DNA binding domain. These results suggest that the inhibitory domain acts by decreasing the activity of the basal transcriptional complex but that it operates indirectly by recruiting a second cell type-specific factor to the promoter which then interacts with the basal complex decreasing its activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.